Providing exclusive access to the future of biotech — combining curated deal flow, deep analysis, and a network of leading scientists, operators, and investors.
San Francisco, CA
Joined May 2016
- Tweets1.7K
- Following334
- Followers1.2K
- Likes869
Nature’s chemistry, powered by AI, meets clinic readiness—a potent formula. Enveda @enveda is building the library of life, with direct routes to human therapeutics.
Congrats @viswacolluru and the entire Enveda team!
Bioverge retweeted
Today’s spotlight in #TimesSquare marks more than our Series D raise and #unicorn milestone. It is a reflection of the bold vision and relentless work of our team, who are advancing a new standard in drug discovery and building a generational company.
Moments like this remind us why we started and what we are capable of achieving together. Seeing Enveda featured on the @Nasdaq Tower is a proud milestone... and it's just the beginning. Thank you for featuring Enveda!
#AI #DrugDiscovery #Nature
Bioverge retweeted
How we built a unicorn from seed in 5 years…
There are no secrets, but purpose, pace, and an incredible team certainly help.
“We’re combining ancient ancestral wisdom with the power of nature’s chemistry with modern AI and drug discovery,” Colluru said. “We’re standing on the shoulders of maybe the giant, which is Mother Nature.”
Read more by @damiangarde in @business about how we raised our Series D, advanced our lead candidate in atopic dermatitis to Phase 1b, and brought on a pharma legend Mikael Dolsten as we prepare to enter more programs in the clinic this year... and stay tuned for more.
#Unicorn #Startups #AI #DrugDiscovery #Nature
Biotech’s latest unicorn Enveda want to use AI to scour thousands of plants for potential medicinal breakthroughs bloomberg.com/news/articles/…
Bioverge retweeted
Today @AltoNeuro began trading on the @NYSE under the ticker $ANRO. I founded Alto out of the desire to give patients better treatment options than those that are currently available. Today we take one step closer to our goal of making #PrecisionPsychiatry a reality.
Bioverge retweeted
🔔 And just like that, Alto is trading on @NYSE!
We are thrilled to be taking this next step as a company and furthering our mission to redefine psychiatry via personalized and highly effective treatment options in #MentalHealth. $ANRO
The January edition of Bioverge Monthly is out!
Discover more about the surge of optimism resulting from a dynamic M&A market and gain insights into the current trends in the private markets.
open.substack.com/pub/biover…
Thrilled to welcome @2kstead @DCVCBio to the pod to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AI.
bioverge.com/blog/copy-copy-…
On our latest pod, @AndrewWLo, Prof @MITSloan sits down with @njlittman to discuss his application of portfolio theory to address the challenges of funding drug development, and how a Netflix subscription model can address funding for advanced therapies.
(link below)
ICYMI: On the pod, Nathan Hunkapiller, CEO of Curve Biosciences, discusses liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of #chronicdisease, and how it is enabling earlier intervention
bioverge.com/blog/the-biover…
Bioverge retweeted
Today we announced the successful close of an oversubscribed $45 million Series C Financing. Read more here: brnw.ch/21wEDXw
The Bioverge Monthly Newsletter November edition is out!
Macro: "In the past three months, we've experienced a pronounced yield curve shift, specifically a bear steepening driven by long-term rate changes."
And the first-ever CRISPR Drug approval!
open.substack.com/pub/biover…
On the latest pod, @fahmadny, CEO of @cure8bio, discusses the company’s growing portfolio of regenerative medicines, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.
Listen today: bioverge.com/blog/the-biover…
On the latest pod, Nathan Hunkapiller, CEO of Curve Biosciences, discusses liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.
bioverge.com/blog/the-biover…
Exciting clinical results from our portfolio company @AltoNeuro further validating their platform and approach to treating neuropsychiatric disorders!
We just announced positive results from the PTSD cohort in our Phase 2a study of ALTO-100, further validating Alto’s Precision Psychiatry Platform™ and drug development approach. Read the full press release here: altoneuroscience.com/press-r…
Bioverge retweeted
We are proud to be selected by the @endpts editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! endpts.com/the-endpoints-11-…
